Research Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low.The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists.Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed. Results. We achieved a response rate of 21%. Clinical T3/T4 disease was themost often selected reason for recommendingNAC (87%). Concerns with recommendingNACwere age and comorbidities (54%) followed by delay in surgery (35%). An association was identified between urologic oncologists who discussed NAC with>90 % of their patients and medical oncologists “always ” recommending NAC